Nyvepria (pegfilgrastim-apgf) NDC 0069-0324

NDC codes

FDA NDC Directory

Product NDC (as listed)0069-0324Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00069-0324Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0069-0324-01	00069032401	1 CARTON in 1 CARTON (0069-0324-01) / 1 SYRINGE in 1 CARTON / .6 mL in 1 SYRINGEMarketed from Dec 15, 2020

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Nyvepria
Generic name (nonproprietary): pegfilgrastim-apgf
Active ingredients: Pegfilgrastim — 6 mg/.6mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Pfizer Laboratories Div Pfizer Inc
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761111
Marketing start: Dec 15, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Granulocyte Colony-Stimulating Factor (Chemical structure)Increased Myeloid Cell Production (Physiologic effect)
Identifiers: Product ID 0069-0324_e562b389-581e-4cf2-a09d-0bd6093d9027SPL ID e562b389-581e-4cf2-a09d-0bd6093d9027SPL set ID 99d30b99-2743-446b-98f3-0430bf4ea869RxCUI 2469335, 2469340UNII 3A58010674
Pharmacologic class: Leukocyte Growth Factor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J2506 — Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Billing unit: 0.5 mg. Units on the claim = dose given ÷ 0.5 mg.

Pegfilgrastim biosimilars have their own HCPCS codes.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400069032401 followed by a unit qualifier and the quantity

Package 00069-0324-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 2, 2026.

Indications (excerpt from the label)

Patients with Cancer Receiving Myelosuppressive Chemotherapy NYVEPRIA is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Dosage and Administration (2.1) and Clinical Studies (14) ] . NYVEPRIA is a leukocyte growth factor indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)